KR101299707B1 - 활성제 전달용 화합물 및 조성물 - Google Patents

활성제 전달용 화합물 및 조성물 Download PDF

Info

Publication number
KR101299707B1
KR101299707B1 KR1020067026383A KR20067026383A KR101299707B1 KR 101299707 B1 KR101299707 B1 KR 101299707B1 KR 1020067026383 A KR1020067026383 A KR 1020067026383A KR 20067026383 A KR20067026383 A KR 20067026383A KR 101299707 B1 KR101299707 B1 KR 101299707B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
solution
another embodiment
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067026383A
Other languages
English (en)
Korean (ko)
Other versions
KR20070024604A (ko
Inventor
마리아 이사벨 고메스-오렐라나
데이비드 그쉬나이드너
안드레아 레오니-베이
데스타디 모이-셔먼
스티븐 브이. 퍼체이
파슈람 라쓰
핑와 탕
존 제이. 웨이드너
쟝펭 송
Original Assignee
에미스페어 테크놀로지스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에미스페어 테크놀로지스, 인코포레이티드 filed Critical 에미스페어 테크놀로지스, 인코포레이티드
Publication of KR20070024604A publication Critical patent/KR20070024604A/ko
Application granted granted Critical
Publication of KR101299707B1 publication Critical patent/KR101299707B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020067026383A 2004-05-14 2005-05-16 활성제 전달용 화합물 및 조성물 Expired - Fee Related KR101299707B1 (ko)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US57108904P 2004-05-14 2004-05-14
US57119404P 2004-05-14 2004-05-14
US57109004P 2004-05-14 2004-05-14
US57109304P 2004-05-14 2004-05-14
US57119504P 2004-05-14 2004-05-14
US57115104P 2004-05-14 2004-05-14
US57114404P 2004-05-14 2004-05-14
US57105504P 2004-05-14 2004-05-14
US57109204P 2004-05-14 2004-05-14
US57131504P 2004-05-14 2004-05-14
US60/571,315 2004-05-14
US60/571,151 2004-05-14
US60/571,194 2004-05-14
US60/571,092 2004-05-14
US60/571,090 2004-05-14
US60/571,055 2004-05-14
US60/571,195 2004-05-14
US60/571,089 2004-05-14
US60/571,144 2004-05-14
US60/571,093 2004-05-14
US57610504P 2004-06-01 2004-06-01
US57639704P 2004-06-01 2004-06-01
US57608804P 2004-06-01 2004-06-01
US60/576,397 2004-06-01
US60/576,105 2004-06-01
US60/576,088 2004-06-01
PCT/US2005/017309 WO2005112633A2 (en) 2004-05-14 2005-05-16 Compounds and compositions for delivering active agents

Publications (2)

Publication Number Publication Date
KR20070024604A KR20070024604A (ko) 2007-03-02
KR101299707B1 true KR101299707B1 (ko) 2013-08-28

Family

ID=35428769

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067026383A Expired - Fee Related KR101299707B1 (ko) 2004-05-14 2005-05-16 활성제 전달용 화합물 및 조성물

Country Status (12)

Country Link
US (1) US8273794B2 (enExample)
EP (2) EP1756039B1 (enExample)
JP (2) JP5254610B2 (enExample)
KR (1) KR101299707B1 (enExample)
AU (1) AU2005244904B2 (enExample)
CA (1) CA2565188C (enExample)
ES (1) ES2393324T3 (enExample)
IL (2) IL179106A (enExample)
MX (1) MXPA06013252A (enExample)
NO (1) NO20065726L (enExample)
NZ (2) NZ597499A (enExample)
WO (1) WO2005112633A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384914B2 (en) 2003-01-06 2008-06-10 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20050203001A1 (en) 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
FR2880887B1 (fr) * 2005-01-14 2009-01-30 Merck Sante Soc Par Actions Si Derives d'hydroxyphenols, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
US8030271B2 (en) 2005-07-05 2011-10-04 Emisphere Technologies, Inc. Compositions and methods for buccal delivery of human growth hormone
SG184730A1 (en) 2005-08-19 2012-10-30 Amylin Pharmaceuticals Inc Methods for treating diabetes and reducing body weight
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
CA2649932A1 (en) 2006-05-02 2007-11-15 Actogenix Nv Microbial intestinal delivery of obesity related peptides
WO2007133944A2 (en) 2006-05-09 2007-11-22 Emisphere Technologies, Inc. Topical administration of acyclovir
AU2007285827A1 (en) * 2006-08-17 2008-02-21 Wellstat Therapeutics Corporation Combination treatment for metabolic disorders
WO2008112368A2 (en) * 2007-02-08 2008-09-18 Emisphere Technologies, Inc. Phenylalkylcarboxylic acid delivery agents
ES2552646T3 (es) 2008-05-21 2015-12-01 Amylin Pharmaceuticals, Inc. Exendinas para disminuir el colesterol y los triglicéridos
JP5985985B2 (ja) * 2009-08-03 2016-09-06 エミスフィアー テクノロジーズ インコーポレイテッドＥｍｉｓｐｈｅｒｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ，Ｉｎｃ． 胃腸への影響が減少した即効型ナプロキセン組成物
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
EP2696687B1 (en) 2011-04-12 2016-10-26 Novo Nordisk A/S Double-acylated glp-1 derivatives
US10941109B2 (en) 2011-06-13 2021-03-09 Ergon Pharmaceuticals Llc Compositions and methods of treatment using a BCAT1 inhibitor
US9422224B2 (en) * 2011-06-13 2016-08-23 Ergon Pharmaceuticals Llc Methods of treatment using a BCAT1 inhibitor
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
BR112015026325A2 (pt) 2013-05-02 2017-07-25 Novo Nordisk As dosagem oral de compostos glp-1
US9950992B2 (en) 2016-03-14 2018-04-24 West Virginia University Water soluble haloanilide calcium-release calcium channel inhibitory compounds and methods to control bone erosion and inflammation associated with arthritides
US11911445B2 (en) * 2018-01-23 2024-02-27 Gila Therapeutics, Inc. Peptide YY pharmaceutical formulations, compositions, and methods
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35862A (en) 1862-07-08 Improved portable evaporator for saccharine jutces
GB842998A (en) * 1956-11-16 1960-08-04 Ici Ltd Process for the production of carboxylic acids by the oxidation of organic compounds
US3072473A (en) * 1959-10-07 1963-01-08 Us Rubber Co Plant growth regulants
US3510561A (en) 1965-05-20 1970-05-05 Canada Packers Ltd Sulfone-enhanced heparin absorption through mucous membranes
FR2420522A1 (fr) * 1978-03-20 1979-10-19 Unicler Derives de l'acide (m-benzoyl-phenoxy)-2 propionique et leurs applications comme medicaments
US4666902A (en) * 1983-06-20 1987-05-19 Cassella Aktiengesellschaft Tetrahydropyridazinone derivatives, processes for their preparation and their use
USRE35862E (en) 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
FI875101A7 (fi) * 1986-12-03 1988-06-04 Tanabe Seiyaku Co Laktaamijohdannaiset ja niitä sisältävät valmisteet.
FR2616661B1 (fr) 1987-06-19 1991-06-07 Doutremepuich Christian Composition a base de mucopolysaccharides hepariniques, active par voie orale
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US6344213B1 (en) 1996-03-29 2002-02-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5541155A (en) 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6916489B2 (en) 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US5366519A (en) * 1992-12-18 1994-11-22 Chevron Research And Technology Company Fuel additive compositions containing poly(oxyalkylene) hydroxyaromatic esters and poly(oxyalkylene) amines
US5401516A (en) 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US20010003001A1 (en) 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20040062773A1 (en) 1993-04-22 2004-04-01 Emisphere Technologies Inc. Compositions for the delivery of antigens
JP4361601B2 (ja) * 1993-04-22 2009-11-11 エミスフェアー・テクノロジーズ・インク 経口薬剤移送組成物およびその方法
SE9302135D0 (sv) 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1151836C (zh) 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5965121A (en) 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5820881A (en) 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
CA2258264A1 (en) 1996-06-14 1997-12-18 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
WO1998020885A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
EP0886471A4 (en) 1996-11-18 2002-07-17 Emisphere Tech Inc METHODS AND COMPOSITIONS FOR INDUCING ORAL TOLERANCE IN MUZZLES
EP0993831B1 (en) * 1997-02-07 2008-01-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5776888A (en) 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9810456A (pt) * 1997-06-27 2001-09-25 Fujisawa Pharmaceutical Co Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico
IN186245B (enExample) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
AU2845599A (en) 1998-03-05 1999-09-20 Phares Pharmaceutical Research N.V. Pharmaceutical compositions and their use
PT1064298E (pt) * 1998-03-19 2009-01-02 Vertex Pharma Inibidores de caspasas
ES2242412T3 (es) 1998-07-27 2005-11-01 Emisphere Technologies, Inc. Compuestos que permiten administrar agentes activos y composiciones a base de estos compuestos.
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
CN1313439C (zh) 1998-08-07 2007-05-02 艾米斯菲尔技术有限公司 用于送递活性剂的化合物和组合物
WO2000022909A2 (en) * 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
EP1131288A1 (en) * 1998-11-20 2001-09-12 F. Hoffmann-La Roche Ag Pyrrolidine derivatives-ccr-3 receptor antagonists
WO2000040203A2 (en) 1999-01-08 2000-07-13 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds
DE60023841T2 (de) 1999-02-05 2006-05-24 Emisphere Technologies, Inc. Verfahren zur herstellung alkylierter salicylamide
JP4854855B2 (ja) 1999-02-11 2012-01-18 エミスフェアー・テクノロジーズ・インク オキサジアゾール化合物及び活性剤をデリバリーするための組成物
AU3378100A (en) 1999-02-26 2000-09-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL145546A0 (en) 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
JP2003500439A (ja) * 1999-05-28 2003-01-07 アボット・ラボラトリーズ 脂質調節剤を含む新規調合物
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
CA2388240C (en) 1999-11-05 2010-04-20 Emisphere Technologies, Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
DE20022960U1 (de) 1999-11-12 2002-07-25 Emisphere Technologies, Inc., Tarrytown, N.Y. Flüssige Heparinformulierung
WO2001044199A1 (en) 1999-12-16 2001-06-21 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4879433B2 (ja) 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
US6384278B1 (en) 2000-02-04 2002-05-07 Emisphere Technologies, Inc. Boron-mediated amidation of carboxylic acids
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
JP4799794B2 (ja) * 2000-03-21 2011-10-26 エミスフェアー・テクノロジーズ・インク ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
JP2004521857A (ja) * 2000-06-29 2004-07-22 エミスフェアー・テクノロジーズ・インク 活性剤の送達のための化合物及び組成物
US6451814B1 (en) * 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6446795B1 (en) 2000-07-31 2002-09-10 The Gillette Company Towelette packaging
WO2002015959A2 (en) 2000-08-18 2002-02-28 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2001284985A1 (en) 2000-08-18 2002-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2001296865A1 (en) 2000-09-06 2002-03-22 Emisphere Technologies, Inc. (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
ATE429416T1 (de) * 2000-09-06 2009-05-15 Emisphere Tech Inc Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
EP2123293A3 (en) 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
NZ527157A (en) 2001-03-01 2005-04-29 Emisphere Tech Inc Compositions for delivering bisphosphonates
US7700775B2 (en) 2001-03-01 2010-04-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20030225300A1 (en) 2001-04-19 2003-12-04 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
CN100516020C (zh) 2001-09-26 2009-07-22 艾米斯菲尔技术有限公司 通过二羧化物中间体制备苯氧基链烷酸、链烯酸和炔酸及其盐的方法
US7297794B2 (en) 2001-11-13 2007-11-20 Emisphere Technologies, Inc. Phenoxy amine compounds and compositions for delivering active agents
WO2003045331A2 (en) 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
AU2003223158B2 (en) 2002-01-09 2008-01-17 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
US7153983B2 (en) * 2002-03-25 2006-12-26 Council Of Scientific And Industrial Research Chemo-enzymatic process for the preparation of opticaly enriched β-benzyl-γ-butyrolactones
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
WO2004019882A2 (en) * 2002-08-29 2004-03-11 American Diagnostica, Inc. METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE TAFIa ACTIVITY, COMPOUNDS, AND METHODS OF USING THE COMPOUNDS
US7384914B2 (en) * 2003-01-06 2008-06-10 Emisphere Technologies, Inc. Night-time oral insulin therapy
AU2004220544B2 (en) 2003-03-06 2010-06-17 Emisphere Technologies, Inc. Oral insulin therapies and protocol
JP2006519881A (ja) * 2003-03-06 2006-08-31 エミスフィアー テクノロジーズ インコーポレイテッド 経口インスリン治療及びプロトコール
CA2525168A1 (en) 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
US20070005005A1 (en) 2003-08-29 2007-01-04 Wang Fang N Method and apparatus for dosing solids
AU2005240206B2 (en) * 2004-05-06 2011-04-07 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
WO2006017541A2 (en) * 2004-08-03 2006-02-16 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
US8110547B2 (en) * 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil

Also Published As

Publication number Publication date
US8273794B2 (en) 2012-09-25
EP1756039B1 (en) 2012-10-17
JP5634342B2 (ja) 2014-12-03
HK1103718A1 (en) 2007-12-28
IL179106A (en) 2013-11-28
US20080255250A1 (en) 2008-10-16
EP2279732B1 (en) 2019-03-20
IL217713A (en) 2015-09-24
IL179106A0 (en) 2007-03-08
EP1756039A4 (en) 2007-05-02
IL217713A0 (en) 2012-03-29
ES2393324T3 (es) 2012-12-20
EP2279732A3 (en) 2012-04-25
AU2005244904B2 (en) 2011-10-13
NZ597499A (en) 2013-04-26
KR20070024604A (ko) 2007-03-02
JP5254610B2 (ja) 2013-08-07
AU2005244904A1 (en) 2005-12-01
MXPA06013252A (es) 2007-02-28
EP2279732A2 (en) 2011-02-02
WO2005112633A2 (en) 2005-12-01
JP2007537301A (ja) 2007-12-20
CA2565188C (en) 2014-03-04
WO2005112633A3 (en) 2006-10-26
JP2011236230A (ja) 2011-11-24
EP1756039A2 (en) 2007-02-28
NZ551196A (en) 2010-08-27
CA2565188A1 (en) 2005-12-01
NO20065726L (no) 2007-02-14

Similar Documents

Publication Publication Date Title
KR101299707B1 (ko) 활성제 전달용 화합물 및 조성물
JP4850379B2 (ja) 活性剤を輸送するための化合物及び組成物
US7351741B2 (en) Compounds and compositions for delivering active agents
US7390834B2 (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
US7462368B2 (en) Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino]butanoate
JP4854855B2 (ja) オキサジアゾール化合物及び活性剤をデリバリーするための組成物
JP2003528822A (ja) 活性剤を送達するための化合物および組成物
JP4995080B2 (ja) 活性薬剤を送達するためのアリールケトン化合物および組成物
AU2012200214B2 (en) Compounds and compositions for delivering active agents
CN1964939B (zh) 传递活性剂的化合物和组合物
JP5564255B2 (ja) プロピルフェノキシエーテルの合成および送達剤としての使用
RU2530889C2 (ru) Соединения и составы для доставки активных веществ
HK1150559A (en) Compounds and compositions for delivering active agents
HK1103718B (en) Compounds and compositions for delivering active agents
IL153297A (en) Compounds and compositions for delivering active agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160629

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170820

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170820